New Products

News

Videos

Reviews

Forums

Search Medcompare

Enter Keyword(s):

Articles

	Laboratory Information Systems – Today’s Hot Topics & Technology

> > > Androstenedione EIA Test

Androstenedione EIA Test

General Information

Vendor		Diagnostic Systems Laboratories, Inc.
Item		Androstenedione EIA Test
Features		Inquire
Approval		For In Vitro Diagnostic Use
Product Number		DSL-10-3800
Size		96 wells
Range		6, 0.1 - 10 ng/mL
Sample Type		Serum, Plasma
Sensitivity		0.03 ng/mL
Incubation Time		1 hr + 10-15 mins on shaker at RT
Storage / Stability		18 mths
Sample Size		25 µL
Pretreatment		None
Format / Method		Coated Well EIA
Pricing		Inquire
Financing		To finance this purchase click here (U.S. customers only)

Product Description

Androstenedione, produced in the adrenal gland and gonads, is the immediate precursor to both testosterone and estrone, both of which may be subsequently converted to estradiol. Androstenedione has relatively weak androgenic activity, estimated at ~(less than or equal to) 20% of testosterone [1]. However, serum androstenedione levels often exceed testosterone in both normal and disease states. Secretion and production rates also exceed those of testosterone in women in whom significant extra-adrenal conversion of androstenedione to testosterone occurs [1,2,3].

Measurement of serum androstenedione provides a useful marker of androgen biosynthesis. Elevated androstenedione levels have been demonstrated in virilizing congenital adrenal hyperplasia [4]. Serum androstenedione levels are also increased in polycystic ovary syndrome, ovarian stromal hyperthecosis, 3b-hydroxysteroid dehydrogenase deficiency, and other causes of hirsutism in women [3,5]. Elevated serum androstenedione levels may also occur in adrenal and ovarian virilizing tumors [3].

1. Dorfman RI, Shipley RA: Androgens. John Wiley and Sons, New York, 1956, pp.116-128.
Horton R, Tait J: Androstenedione production and interconversion rates measured in peripheral blood and studies on the possible site of its conversion to testosterone. J Clin Invest 45:301-313, 1966.
Pang S, Riddick L: Hirsutism. IN Lifshitz F (ed): Pediatric Endocrinology, A Clinical Guide, second edition. Marcel Dekker, Inc., New York, 1990, pp. 259-291.
Cavallo A, Corn C, Bryan GT, Meyer WJ III: The use of plasma androstenedione in monitoring therapy of patients with congenital adrenal hyperplasia. J Pediatr 95: 33-37, 1979.
Rittmaster RS, Thompson DL: Effects of leuprolide and dexamethasone on hair growth and hormone levels in hirsute women: the relative importance of the ovary and adrenal in the pathogenesis of hirsutism. J Clin Endocrinol Metab 70:1096-1102, 1990.
Zwicker H, Rittmaster RS: Androsterone sulfate: physiology and significance in hirsute women. J Clin Endocrinol Metab 76:112-116, 1993.
Barrett-Connor E, Garland C, McPhillips JB, Khaw K-T, Wingard DL: A prospective, population-based study of androstenedione, estrogens, and prostate cancer. Canc Res 50:169-173, 1990.

NOTE: Medcompare disclaims any information on this site. The information found on Medcompare (Drug Guide, Product Listings and otherwise) is intended for use by medical professionals. This information is not intended to replace the information, advice or instructions from a medical doctor. Pricing information is approximate, actual prices may vary.